You are here: Home » PTI Stories » National » News
Business Standard

Aurobindo Pharma down 4% on USFDA observations for Hyd unit

Press Trust of India  |  New Delhi 

of Pharma today fell by nearly 4 per cent after the company said that US health regulator has issued observations for its Unit III formulations facility in

The stock went down by 3.53 per cent to end at Rs 640.20 on During the day, it dipped 4.68 per cent to Rs 632.50.

On NSE, of the company slipped 3.65 per cent to close at Rs 640.05.

On the volume front, 3.63 lakh of the company were traded on and over 30 lakh shares changed hands on during the day.

The United States Food and Drug Administration (USFDA) had conducted an inspection at the company's Unit III, a formulations manufacturing facility at Bachupally, from April 10-18, Pharma said in a filing.

"At the end of the inspection, we have been issued a Form 483 with 6 observations. The observations are all on procedural improvements," it added.

As per the USFDA, a Form 483 is issued to a company's management at the conclusion of an inspection when "an investigator(s) has observed any conditions that in their judgement may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts".

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Wed, April 19 2017. 16:43 IST